Related Experiment Video

Updated: Aug 19, 2026

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
09:47

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique

Published on: April 26, 2015

Carvedilol in hypertension

E B Raftery1

  • 1Division of Cardiovascular Diseases, Northwick Park Hospital, Harrow, Middlesex, UK.

Cardiology
|January 1, 1993
PubMed

Insights

Beta-blockers effectively lower blood pressure during the day but not in the morning. Combining them with a diuretic or using carvedilol (a beta-blocker with alpha-blocking activity) offers sustained 24-hour blood pressure control.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research
  • Pharmacodynamics

Background:

  • Ambulatory intra-arterial blood pressure monitoring offers precise, objective assessment of antihypertensive drug efficacy.
  • Beta-adrenoceptor-blocking drugs demonstrate limited effectiveness against the early-morning rise in blood pressure, a period of high sympathetic activity.

Purpose of the Study:

  • To evaluate the 24-hour efficacy of beta-blockers and the impact of diuretic addition.
  • To characterize the action profile of carvedilol, a combined beta- and alpha-blocker.

Main Methods:

  • Utilized ambulatory intra-arterial blood pressure monitoring to assess drug effects.
  • Investigated the effects of beta-blockers alone, in combination with diuretics, and carvedilol on blood pressure patterns.

Main Results:

  • Beta-blockers showed efficacy primarily during active daytime hours, with minimal impact on the morning blood pressure surge.
  • The addition of a diuretic to beta-blocker therapy resulted in consistent, 24-hour blood pressure reduction.
  • Carvedilol's dual alpha- and beta-blocking activity mimicked the effects of combined beta-blocker and diuretic therapy.

Conclusions:

  • Carvedilol's single-molecule dual-action offers a potentially advantageous therapeutic approach for sustained blood pressure management.
  • Combined beta-blocker and diuretic therapy provides more comprehensive 24-hour blood pressure control compared to beta-blockers alone.

More Related Videos

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...